2016 Meetings

December 2016 Meetings

AGAR Executive Meeting Minutes December 2016 (PDF)
December 2016 AGAR Executive Agenda (PDF)
2.0 AGAR July 2016 Minutes (PDF)
3.1 Potential New Vitek2 ANZ Cards (PDF)
3.2 Potential New Vitek2 Eucast Cards (PDF)
3.3 AGAR Vitek Proposed Susceptibility Cards (PDF)
3.4 AGAR Vitek Proposed Susceptibility Cards (PDF)
3.5 More Questions GN (PDF)
3.6 More Questions (PDF)
3.7 Package insert 22359 (PDF)
3.8 Package insert 9302781 (PDF)
3.9 Package insert 9307160 (PDF)
5. AGAR Operating Procedures 2016 (PDF)
7.1 September 2016 Financial Report (PDF)
8.1 Final AGAR 2015 Financial Report (PDF)
9.1 Deed of Variation 2 Draft (PDF)
9.2 Proposed 2016 AGAR Budget (PDF)
10. Proposed AGAR 2017 Budget (PDF)
12.1 AGAR Working Groups Financial Report (PDF)
13.1 ACSQHC ASSOP 2015 Report (PDF)
13.2 ACSQHC AESOP 2015 Report (PDF)
13.3 ACSQHC GNSOP 2015 Report (PDF)
13.4 ACSQHC Combined 2015 Report (PDF)
20.1 AGAR Online Web Portal (PDF)
21.1 Jan Bell Funding (PDF)
21.2 AGAR Teleconference 6 August 2016 (PDF)
22.1 Baltimore USA (PDF)
22.2 RCPAQAP (PDF)
24.1 Implementation Plan for National AMR Strategy (PDF)
25.1 MRSA – A Tale of Three Types (PDF)
25.3 ACSQHC Data Governance Framework (PDF)

July 2016 Meetings:

AGAR Program Chairs Meeting Minutes July 2016 (PDF)
AGAR July 2016 Executive Agenda (PDF)
AGAR Executive Meeting Minutes July 2016 (PDF)
December 2015 Minutes (PDF)
4.1 George Kotsiou (PDF)
4.2 Ben Rogers (PDF)
4.3 Asha Bowen (PDF)
4.4 CDI AESOP 2014 (PDF)
4.5 CDI ASSOP 2014 (PDF)
4.6 Peter Ward (PDF)
4.7 John Turnidge (PDF)
4.8 Lena Lee (PDF)
4.9 Lena Lee (PDF)
4.10 Request for publication from National Library (PDF)
4.11 Kathy Meleady (PDF)
4.12 AURA 2016 Report (PDF)
4.13 Emma Goeman (PDF)
5.1 AGAR Operating Procedures 2016 (PDF)
7.1 AGAR December 2015 and March 2016 Financial Report (PDF)
7.2 AGAR June 2016 Report (PDF)
7.3 AGAR 2015 2016 Financial Report (PDF)
8.1 2015 AGAR Budget (PDF)
8.2 2015 Project Plan (PDF)
8.3 2015 Contract for Services (PDF)
8.4 2015 Deed of Variation (PDF)
8.4.1 S. pneumoniae Program (PDF)
10.1 Financial Report (PDF)
10.2.1.1. Baines (PDF)
10.2.1.2.Guilieri (PDF)
10.2.1.3. Williamson (PDF)
11.1 CDI AESOP 2014 Publication (PDF)
12.1 CDI ASSOP 2014 Publication (PDF)
13.1 CDI EnSOP 2014 Publication (PDF)
14. AESOP 2015 Final Report (PDF)
15. ASSOP 2015 Final Report (PDF)
16. GNSOP 2015 Final Report (PDF)
21.1 Sharon Tennant(PDF)
24.1 Doherty Institute MOU (PDF)
24.2 Louise Cooley (PDF)
24.3 Asha Bowen (PDF)
29.4.1 Mayne Pharma Fosfomycin (PDF)
29.4.2 Mayne Pharma Fosfomycin 2 (PDF)
29.4.3 Mayne Pharma Confidentiality Agreement (PDF)
29.4.4 Mayne Pharma Post Marketing Surveillance (PDF)
29.5.1 Nicky Duly (PDF)
29.5.2 Package Insert 22359-P612 (PDF)
29.5.3 Package Insert 9302781-A-413395 (PDF)
29.5.4 Package Insert 9307160-A-4169521 (PDF)
29.5.5 Vitek 2 Card Offering ANZ (Excel)

Copyright © 2004-2022 Australian Group on Antimicrobial Resistance (AGAR). Last Updated December 2017.